Larry Gold
Concepts (330)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Aptamers, Nucleotide | 9 | 2016 | 73 | 2.130 |
Why?
| RNA | 24 | 2020 | 809 | 1.990 |
Why?
| SELEX Aptamer Technique | 7 | 2016 | 14 | 1.390 |
Why?
| Proteomics | 11 | 2014 | 836 | 1.380 |
Why?
| T-Phages | 15 | 1991 | 22 | 1.200 |
Why?
| Nucleic Acid Conformation | 33 | 2000 | 669 | 1.110 |
Why?
| RNA, Catalytic | 4 | 2020 | 182 | 1.100 |
Why?
| Base Sequence | 53 | 2003 | 2114 | 1.090 |
Why?
| Escherichia coli | 23 | 1997 | 720 | 1.060 |
Why?
| Molecular Sequence Data | 53 | 2012 | 2785 | 1.020 |
Why?
| Viral Proteins | 14 | 1997 | 281 | 0.820 |
Why?
| Oligoribonucleotides | 10 | 1997 | 52 | 0.810 |
Why?
| Biomarkers | 9 | 2015 | 3408 | 0.760 |
Why?
| DNA, Single-Stranded | 7 | 2003 | 111 | 0.750 |
Why?
| Ligands | 22 | 2016 | 561 | 0.740 |
Why?
| RNA, Messenger | 15 | 2000 | 2552 | 0.700 |
Why?
| Ribosomes | 12 | 1995 | 148 | 0.700 |
Why?
| Proteome | 6 | 2014 | 339 | 0.700 |
Why?
| Ribonucleotides | 1 | 2020 | 24 | 0.690 |
Why?
| Oligodeoxyribonucleotides | 8 | 2003 | 138 | 0.650 |
Why?
| Reverse Transcriptase Inhibitors | 6 | 1996 | 82 | 0.630 |
Why?
| Proteins | 9 | 2014 | 908 | 0.590 |
Why?
| Genes, Viral | 11 | 1995 | 89 | 0.550 |
Why?
| Protein Biosynthesis | 10 | 1997 | 385 | 0.530 |
Why?
| Peptide Chain Initiation, Translational | 6 | 1995 | 38 | 0.530 |
Why?
| Binding Sites | 23 | 2000 | 1168 | 0.510 |
Why?
| HIV-1 | 8 | 1996 | 768 | 0.490 |
Why?
| RNA, Viral | 10 | 2000 | 565 | 0.490 |
Why?
| Blood Proteins | 3 | 2015 | 231 | 0.490 |
Why?
| Muscular Dystrophy, Duchenne | 1 | 2015 | 80 | 0.460 |
Why?
| Oligonucleotides | 4 | 2011 | 137 | 0.460 |
Why?
| Q beta Replicase | 4 | 1996 | 4 | 0.430 |
Why?
| RNA, Ribosomal | 1 | 2014 | 157 | 0.430 |
Why?
| DNA | 4 | 2011 | 1352 | 0.410 |
Why?
| Diagnosis | 2 | 2013 | 9 | 0.410 |
Why?
| Capsid | 3 | 2000 | 75 | 0.410 |
Why?
| Bacteriophage T4 | 4 | 1997 | 15 | 0.400 |
Why?
| Kinetics | 14 | 2010 | 1551 | 0.350 |
Why?
| Polymerase Chain Reaction | 15 | 2000 | 993 | 0.350 |
Why?
| Protein Binding | 13 | 2014 | 1889 | 0.350 |
Why?
| Gene Products, rev | 2 | 2002 | 5 | 0.340 |
Why?
| HIV Reverse Transcriptase | 5 | 1996 | 29 | 0.330 |
Why?
| History, 20th Century | 3 | 2015 | 264 | 0.310 |
Why?
| DNA-Directed DNA Polymerase | 3 | 1997 | 44 | 0.310 |
Why?
| Capsid Proteins | 2 | 2000 | 69 | 0.310 |
Why?
| Evolution, Molecular | 4 | 2020 | 430 | 0.310 |
Why?
| Bacterial Proteins | 4 | 1996 | 736 | 0.310 |
Why?
| Information Systems | 3 | 1998 | 61 | 0.300 |
Why?
| RNA, Bacterial | 4 | 2000 | 174 | 0.300 |
Why?
| Biological Evolution | 5 | 2014 | 416 | 0.290 |
Why?
| RNA-Binding Proteins | 4 | 2000 | 344 | 0.290 |
Why?
| RNA, Transfer | 4 | 1991 | 118 | 0.270 |
Why?
| DNA-Binding Proteins | 5 | 1993 | 1314 | 0.270 |
Why?
| Directed Molecular Evolution | 2 | 1996 | 21 | 0.270 |
Why?
| RNA Processing, Post-Transcriptional | 4 | 1996 | 82 | 0.260 |
Why?
| DNA Primers | 10 | 2012 | 510 | 0.260 |
Why?
| Bacteriophages | 2 | 2000 | 75 | 0.260 |
Why?
| RNA-Directed DNA Polymerase | 5 | 1996 | 34 | 0.250 |
Why?
| Protein Array Analysis | 3 | 2014 | 56 | 0.240 |
Why?
| Clinical Laboratory Techniques | 2 | 2003 | 87 | 0.240 |
Why?
| Gene Library | 2 | 2010 | 114 | 0.240 |
Why?
| Cloning, Molecular | 11 | 1998 | 522 | 0.240 |
Why?
| Tenascin | 1 | 2003 | 13 | 0.230 |
Why?
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 740 | 0.220 |
Why?
| Templates, Genetic | 6 | 2003 | 59 | 0.220 |
Why?
| Biomarkers, Tumor | 3 | 2012 | 1040 | 0.210 |
Why?
| Amino Acid Sequence | 9 | 2003 | 1982 | 0.210 |
Why?
| Peptide Initiation Factors | 3 | 1993 | 17 | 0.210 |
Why?
| DNA, Bacterial | 5 | 1997 | 311 | 0.200 |
Why?
| Plasmids | 6 | 1992 | 343 | 0.190 |
Why?
| Drug Evaluation, Preclinical | 1 | 2002 | 161 | 0.190 |
Why?
| Codon | 7 | 1994 | 86 | 0.190 |
Why?
| Protein Interaction Mapping | 1 | 2002 | 101 | 0.190 |
Why?
| Bacteriophage lambda | 3 | 1992 | 81 | 0.190 |
Why?
| Genomic Library | 2 | 2000 | 15 | 0.190 |
Why?
| Antibodies | 3 | 2014 | 371 | 0.170 |
Why?
| Combinatorial Chemistry Techniques | 1 | 2000 | 16 | 0.170 |
Why?
| Genome, Bacterial | 1 | 2000 | 106 | 0.170 |
Why?
| Aptamers, Peptide | 2 | 2011 | 3 | 0.170 |
Why?
| Gene Expression Regulation | 6 | 2002 | 2319 | 0.170 |
Why?
| Substrate Specificity | 6 | 2000 | 352 | 0.170 |
Why?
| Neoplasm Proteins | 1 | 2003 | 384 | 0.170 |
Why?
| Structure-Activity Relationship | 7 | 2002 | 502 | 0.160 |
Why?
| Humans | 28 | 2016 | 114623 | 0.160 |
Why?
| Nucleic Acids | 2 | 2011 | 59 | 0.150 |
Why?
| Computer Simulation | 3 | 1998 | 872 | 0.150 |
Why?
| Recombinant Proteins | 7 | 2014 | 1230 | 0.150 |
Why?
| Antiviral Agents | 2 | 1995 | 645 | 0.150 |
Why?
| Mass Spectrometry | 4 | 2010 | 633 | 0.150 |
Why?
| Chloramphenicol | 1 | 1997 | 6 | 0.150 |
Why?
| Peptidyl Transferases | 1 | 1997 | 7 | 0.150 |
Why?
| Erythrocyte Membrane | 1 | 1998 | 50 | 0.150 |
Why?
| Ribosomal Proteins | 2 | 1995 | 70 | 0.150 |
Why?
| Reproducibility of Results | 4 | 2011 | 2762 | 0.150 |
Why?
| DNA, Viral | 4 | 1993 | 350 | 0.140 |
Why?
| S-Adenosylmethionine | 1 | 1997 | 54 | 0.140 |
Why?
| Binding, Competitive | 5 | 1996 | 193 | 0.140 |
Why?
| Guanosine Monophosphate | 1 | 1996 | 7 | 0.140 |
Why?
| Models, Molecular | 4 | 2012 | 1369 | 0.140 |
Why?
| Repressor Proteins | 3 | 1996 | 366 | 0.140 |
Why?
| Gene Products, gag | 1 | 1996 | 36 | 0.140 |
Why?
| Bradykinin | 1 | 1996 | 42 | 0.140 |
Why?
| Molecular Biology | 1 | 1997 | 56 | 0.140 |
Why?
| Nucleic Acid Hybridization | 2 | 2010 | 187 | 0.130 |
Why?
| DNA Replication | 3 | 1993 | 202 | 0.130 |
Why?
| Endoribonucleases | 1 | 1996 | 62 | 0.130 |
Why?
| DNA Nucleotidyltransferases | 1 | 1995 | 11 | 0.130 |
Why?
| Base Composition | 4 | 1996 | 75 | 0.130 |
Why?
| RNA, Antisense | 2 | 1992 | 17 | 0.130 |
Why?
| Adenosine | 1 | 1997 | 203 | 0.130 |
Why?
| Nerve Growth Factors | 1 | 1995 | 71 | 0.120 |
Why?
| Substance P | 1 | 1995 | 44 | 0.120 |
Why?
| Eye Diseases | 1 | 2016 | 76 | 0.120 |
Why?
| Transcription, Genetic | 5 | 2000 | 1313 | 0.120 |
Why?
| Ribonucleases | 1 | 1994 | 52 | 0.120 |
Why?
| Ophthalmology | 1 | 2016 | 77 | 0.120 |
Why?
| Consensus Sequence | 5 | 2000 | 70 | 0.120 |
Why?
| Models, Theoretical | 1 | 1998 | 515 | 0.120 |
Why?
| Enzyme Inhibitors | 1 | 1997 | 750 | 0.120 |
Why?
| Escherichia coli Proteins | 1 | 1996 | 162 | 0.120 |
Why?
| Origin of Life | 1 | 2014 | 9 | 0.120 |
Why?
| RNA, Transfer, Amino Acid-Specific | 1 | 1994 | 4 | 0.120 |
Why?
| Selenocysteine | 1 | 1994 | 3 | 0.120 |
Why?
| RNA, Transfer, Amino Acyl | 1 | 1994 | 8 | 0.120 |
Why?
| Hydrolysis | 4 | 1997 | 173 | 0.120 |
Why?
| Peptide Elongation Factors | 1 | 1994 | 13 | 0.110 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 797 | 0.110 |
Why?
| Genetic Techniques | 2 | 2010 | 58 | 0.110 |
Why?
| Genetic Vectors | 2 | 1992 | 289 | 0.110 |
Why?
| Sensitivity and Specificity | 4 | 2010 | 1691 | 0.110 |
Why?
| Catalysis | 3 | 2002 | 289 | 0.110 |
Why?
| Operator Regions, Genetic | 2 | 1990 | 6 | 0.110 |
Why?
| History, 21st Century | 1 | 2014 | 159 | 0.110 |
Why?
| Carcinoma, Non-Small-Cell Lung | 2 | 2012 | 961 | 0.110 |
Why?
| Models, Genetic | 3 | 1991 | 562 | 0.110 |
Why?
| Proto-Oncogene Proteins c-sis | 1 | 2012 | 35 | 0.100 |
Why?
| Case-Control Studies | 3 | 2015 | 3003 | 0.100 |
Why?
| Drug Therapy | 1 | 2013 | 76 | 0.100 |
Why?
| Genes, pX | 1 | 1992 | 2 | 0.100 |
Why?
| Deoxyribonuclease EcoRI | 1 | 1992 | 5 | 0.100 |
Why?
| Body Fluids | 1 | 2012 | 58 | 0.100 |
Why?
| Mutation | 7 | 1995 | 3344 | 0.100 |
Why?
| Affinity Labels | 2 | 2014 | 25 | 0.100 |
Why?
| Hydrophobic and Hydrophilic Interactions | 1 | 2012 | 176 | 0.100 |
Why?
| Diagnostic Techniques and Procedures | 1 | 2011 | 13 | 0.100 |
Why?
| Electrophoresis, Polyacrylamide Gel | 4 | 1993 | 318 | 0.100 |
Why?
| Ribonucleotide Reductases | 1 | 1991 | 21 | 0.090 |
Why?
| RNA, Ribosomal, 16S | 1 | 1993 | 485 | 0.090 |
Why?
| DNA Transposable Elements | 1 | 1992 | 101 | 0.090 |
Why?
| Sequence Homology, Nucleic Acid | 4 | 1995 | 152 | 0.090 |
Why?
| Biological Assay | 1 | 2011 | 112 | 0.090 |
Why?
| Chromosome Deletion | 1 | 1991 | 95 | 0.090 |
Why?
| Animals | 7 | 2014 | 31694 | 0.090 |
Why?
| Neoplasms | 2 | 2012 | 2097 | 0.090 |
Why?
| Transcription Factors | 2 | 1989 | 1528 | 0.090 |
Why?
| Anti-HIV Agents | 1 | 1996 | 666 | 0.090 |
Why?
| Introns | 1 | 1991 | 227 | 0.090 |
Why?
| Promoter Regions, Genetic | 3 | 1991 | 1131 | 0.090 |
Why?
| Micrococcal Nuclease | 1 | 1989 | 19 | 0.080 |
Why?
| Genes, Regulator | 1 | 1989 | 34 | 0.080 |
Why?
| Databases, Protein | 1 | 2009 | 59 | 0.080 |
Why?
| Lung Neoplasms | 2 | 2012 | 2177 | 0.080 |
Why?
| Exodeoxyribonucleases | 1 | 1988 | 24 | 0.080 |
Why?
| Metalloproteins | 1 | 1987 | 5 | 0.080 |
Why?
| Computational Biology | 2 | 2003 | 530 | 0.070 |
Why?
| Trans-Activators | 1 | 1990 | 367 | 0.070 |
Why?
| Cohort Studies | 2 | 2015 | 4894 | 0.070 |
Why?
| Glomerular Filtration Rate | 1 | 2010 | 604 | 0.070 |
Why?
| Early Detection of Cancer | 1 | 2010 | 328 | 0.070 |
Why?
| Avian Myeloblastosis Virus | 3 | 1996 | 4 | 0.070 |
Why?
| Societies | 1 | 2007 | 38 | 0.070 |
Why?
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 1141 | 0.070 |
Why?
| Hydrogen-Ion Concentration | 3 | 2004 | 511 | 0.070 |
Why?
| Evidence-Based Medicine | 1 | 2010 | 668 | 0.070 |
Why?
| Genes, Bacterial | 2 | 2000 | 157 | 0.070 |
Why?
| Sequence Analysis | 2 | 1996 | 35 | 0.070 |
Why?
| Oligonucleotide Probes | 3 | 1991 | 54 | 0.070 |
Why?
| Peptide Fragments | 2 | 2003 | 665 | 0.070 |
Why?
| Conserved Sequence | 2 | 1997 | 218 | 0.060 |
Why?
| Kidney Failure, Chronic | 1 | 2010 | 489 | 0.060 |
Why?
| Membrane Proteins | 2 | 2003 | 1018 | 0.060 |
Why?
| Mathematics | 2 | 1998 | 101 | 0.060 |
Why?
| Zinc | 1 | 1987 | 260 | 0.060 |
Why?
| Models, Biological | 1 | 1991 | 1620 | 0.060 |
Why?
| United States | 2 | 2015 | 12176 | 0.060 |
Why?
| Macromolecular Substances | 2 | 1996 | 200 | 0.060 |
Why?
| DNA, Fungal | 2 | 1997 | 69 | 0.060 |
Why?
| RNA, Transfer, Met | 2 | 1994 | 6 | 0.060 |
Why?
| Molecular Structure | 2 | 2012 | 434 | 0.060 |
Why?
| Hydrogen Bonding | 2 | 1994 | 143 | 0.060 |
Why?
| Selection, Genetic | 2 | 1998 | 242 | 0.060 |
Why?
| beta-Galactosidase | 3 | 1994 | 62 | 0.060 |
Why?
| Restriction Mapping | 2 | 1995 | 77 | 0.050 |
Why?
| Ultraviolet Rays | 2 | 1996 | 363 | 0.050 |
Why?
| Human Genome Project | 1 | 2003 | 14 | 0.050 |
Why?
| Drug Design | 2 | 1995 | 148 | 0.050 |
Why?
| Isomerism | 2 | 1992 | 43 | 0.050 |
Why?
| Education, Continuing | 1 | 2003 | 39 | 0.050 |
Why?
| Adenosine Triphosphate | 2 | 1997 | 430 | 0.050 |
Why?
| Gene Expression | 3 | 1992 | 1421 | 0.050 |
Why?
| Chromatography, Liquid | 1 | 2003 | 347 | 0.050 |
Why?
| Tumor Cells, Cultured | 1 | 2003 | 849 | 0.050 |
Why?
| Child, Preschool | 1 | 2015 | 9108 | 0.050 |
Why?
| Molecular Diagnostic Techniques | 2 | 2014 | 91 | 0.050 |
Why?
| Sequence Analysis, DNA | 2 | 2012 | 723 | 0.050 |
Why?
| Glioblastoma | 1 | 2003 | 253 | 0.050 |
Why?
| Cross-Linking Reagents | 2 | 2004 | 181 | 0.050 |
Why?
| RNA, Fungal | 2 | 1991 | 66 | 0.050 |
Why?
| Prokaryotic Initiation Factor-3 | 2 | 1990 | 6 | 0.040 |
Why?
| Genome | 1 | 2002 | 271 | 0.040 |
Why?
| Saccharomyces cerevisiae | 2 | 1997 | 476 | 0.040 |
Why?
| In Vitro Techniques | 2 | 1995 | 1016 | 0.040 |
Why?
| Artifacts | 1 | 2000 | 113 | 0.040 |
Why?
| Young Adult | 1 | 2015 | 10455 | 0.040 |
Why?
| Male | 3 | 2015 | 55554 | 0.040 |
Why?
| Genomics | 1 | 2003 | 635 | 0.040 |
Why?
| DNA Mutational Analysis | 2 | 1990 | 372 | 0.040 |
Why?
| RNA, Ribosomal, 23S | 1 | 1997 | 12 | 0.040 |
Why?
| International Cooperation | 2 | 2009 | 171 | 0.040 |
Why?
| Adolescent | 1 | 2015 | 17831 | 0.040 |
Why?
| gag Gene Products, Human Immunodeficiency Virus | 1 | 1996 | 12 | 0.030 |
Why?
| Peptide Elongation Factor Tu | 1 | 1996 | 5 | 0.030 |
Why?
| NAD | 1 | 1997 | 63 | 0.030 |
Why?
| Uridine Triphosphate | 1 | 1996 | 11 | 0.030 |
Why?
| Butanones | 1 | 1996 | 3 | 0.030 |
Why?
| Alkylation | 1 | 1996 | 18 | 0.030 |
Why?
| Metals | 1 | 1997 | 106 | 0.030 |
Why?
| Thionucleotides | 1 | 1996 | 34 | 0.030 |
Why?
| Replicon | 1 | 1996 | 14 | 0.030 |
Why?
| Neoplasm Metastasis | 2 | 2012 | 522 | 0.030 |
Why?
| Sulfur | 1 | 1996 | 46 | 0.030 |
Why?
| Gene Dosage | 1 | 1997 | 129 | 0.030 |
Why?
| Child | 1 | 2015 | 18404 | 0.030 |
Why?
| Aged | 2 | 2012 | 19061 | 0.030 |
Why?
| rev Gene Products, Human Immunodeficiency Virus | 1 | 1995 | 5 | 0.030 |
Why?
| Single-Strand Specific DNA and RNA Endonucleases | 1 | 1995 | 10 | 0.030 |
Why?
| Immunodeficiency Virus, Feline | 1 | 1996 | 30 | 0.030 |
Why?
| Aldehydes | 1 | 1996 | 138 | 0.030 |
Why?
| Buffers | 1 | 1995 | 53 | 0.030 |
Why?
| Magnetic Resonance Spectroscopy | 1 | 1997 | 473 | 0.030 |
Why?
| Viral Structural Proteins | 1 | 1995 | 12 | 0.030 |
Why?
| Mammary Tumor Virus, Mouse | 1 | 1995 | 42 | 0.030 |
Why?
| Viruses | 1 | 1996 | 94 | 0.030 |
Why?
| Sepharose | 1 | 1995 | 31 | 0.030 |
Why?
| Arginine | 1 | 1996 | 238 | 0.030 |
Why?
| Virus Integration | 1 | 1995 | 68 | 0.030 |
Why?
| Enzyme Induction | 1 | 1994 | 84 | 0.030 |
Why?
| Sodium Chloride | 1 | 1995 | 136 | 0.030 |
Why?
| Ribonuclease H | 1 | 1994 | 11 | 0.030 |
Why?
| Leukemia Virus, Murine | 1 | 1994 | 16 | 0.030 |
Why?
| Integrases | 1 | 1995 | 116 | 0.030 |
Why?
| Middle Aged | 2 | 2012 | 26719 | 0.030 |
Why?
| Software | 1 | 1998 | 529 | 0.030 |
Why?
| Selenoproteins | 1 | 1994 | 8 | 0.030 |
Why?
| Peptide Chain Elongation, Translational | 1 | 1994 | 18 | 0.030 |
Why?
| RNA, Transfer, Phe | 1 | 1993 | 9 | 0.030 |
Why?
| DNA, Complementary | 1 | 1994 | 256 | 0.030 |
Why?
| Adult | 1 | 2015 | 30528 | 0.030 |
Why?
| Models, Structural | 1 | 1993 | 37 | 0.030 |
Why?
| Rho Factor | 1 | 1993 | 2 | 0.030 |
Why?
| Electrophoresis | 1 | 1992 | 26 | 0.030 |
Why?
| Chromatography, Affinity | 1 | 1993 | 80 | 0.030 |
Why?
| Transition Temperature | 1 | 2012 | 26 | 0.030 |
Why?
| Mutagenesis, Site-Directed | 1 | 1993 | 345 | 0.030 |
Why?
| Allosteric Regulation | 1 | 1992 | 81 | 0.030 |
Why?
| RNA, Small Untranslated | 1 | 2012 | 15 | 0.030 |
Why?
| Complement Inactivating Agents | 1 | 2013 | 41 | 0.030 |
Why?
| Lac Operon | 1 | 1992 | 44 | 0.030 |
Why?
| Amino Acid Motifs | 1 | 2012 | 197 | 0.030 |
Why?
| Titrimetry | 1 | 2011 | 9 | 0.020 |
Why?
| Random Allocation | 1 | 1992 | 335 | 0.020 |
Why?
| Limit of Detection | 1 | 2011 | 53 | 0.020 |
Why?
| Sequence Analysis, RNA | 1 | 1994 | 385 | 0.020 |
Why?
| Ion Channels | 1 | 1992 | 123 | 0.020 |
Why?
| Automation | 1 | 2011 | 73 | 0.020 |
Why?
| Alkaline Phosphatase | 1 | 1992 | 143 | 0.020 |
Why?
| Nanotechnology | 1 | 2012 | 113 | 0.020 |
Why?
| Crystallography, X-Ray | 1 | 2012 | 402 | 0.020 |
Why?
| Anticodon | 1 | 1991 | 22 | 0.020 |
Why?
| Placenta | 1 | 1997 | 625 | 0.020 |
Why?
| Triticum | 1 | 1990 | 9 | 0.020 |
Why?
| Endodeoxyribonucleases | 1 | 1991 | 59 | 0.020 |
Why?
| Neoplasm Invasiveness | 1 | 2012 | 442 | 0.020 |
Why?
| Databases, Factual | 1 | 1995 | 1124 | 0.020 |
Why?
| Recombination, Genetic | 1 | 1991 | 176 | 0.020 |
Why?
| Sequence Alignment | 1 | 1991 | 323 | 0.020 |
Why?
| Germany | 1 | 1990 | 84 | 0.020 |
Why?
| Data Interpretation, Statistical | 1 | 1992 | 321 | 0.020 |
Why?
| Neovascularization, Pathologic | 1 | 2012 | 281 | 0.020 |
Why?
| Gene Expression Regulation, Viral | 1 | 1990 | 80 | 0.020 |
Why?
| Complement System Proteins | 1 | 2013 | 282 | 0.020 |
Why?
| Tetrahydrofolate Dehydrogenase | 1 | 1989 | 14 | 0.020 |
Why?
| Nervous System Diseases | 1 | 2012 | 253 | 0.020 |
Why?
| Regulatory Sequences, Nucleic Acid | 1 | 1989 | 81 | 0.020 |
Why?
| Database Management Systems | 1 | 2009 | 47 | 0.020 |
Why?
| Recombinant Fusion Proteins | 1 | 1992 | 616 | 0.020 |
Why?
| Open Reading Frames | 1 | 1989 | 116 | 0.020 |
Why?
| Exodeoxyribonuclease V | 1 | 1988 | 8 | 0.020 |
Why?
| Genes | 1 | 1988 | 223 | 0.020 |
Why?
| Phosphorylation | 1 | 2012 | 1569 | 0.020 |
Why?
| Terminology as Topic | 1 | 2009 | 187 | 0.020 |
Why?
| Female | 2 | 2012 | 59466 | 0.020 |
Why?
| RNA Caps | 1 | 1988 | 31 | 0.020 |
Why?
| Genetic Complementation Test | 1 | 1987 | 62 | 0.020 |
Why?
| Gene Conversion | 1 | 1987 | 6 | 0.020 |
Why?
| Models, Statistical | 1 | 2010 | 599 | 0.020 |
Why?
| Europe | 1 | 2007 | 334 | 0.020 |
Why?
| Genetic Variation | 1 | 2010 | 870 | 0.020 |
Why?
| Virus Replication | 1 | 1987 | 395 | 0.020 |
Why?
| Antibodies, Monoclonal | 1 | 1991 | 1262 | 0.010 |
Why?
| Endostatins | 1 | 2004 | 9 | 0.010 |
Why?
| Interleukin-16 | 1 | 2004 | 6 | 0.010 |
Why?
| Lod Score | 1 | 2004 | 65 | 0.010 |
Why?
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2004 | 25 | 0.010 |
Why?
| Fibroblast Growth Factor 2 | 1 | 2004 | 83 | 0.010 |
Why?
| Algorithms | 1 | 2010 | 1466 | 0.010 |
Why?
| Smoking | 1 | 2010 | 1380 | 0.010 |
Why?
| Carrier Proteins | 1 | 1987 | 695 | 0.010 |
Why?
| Autoantibodies | 1 | 2010 | 1345 | 0.010 |
Why?
| Apoptosis | 1 | 2012 | 2362 | 0.010 |
Why?
| Colonic Neoplasms | 1 | 2004 | 215 | 0.010 |
Why?
| Inflammation | 1 | 2012 | 2477 | 0.010 |
Why?
| Light | 1 | 2004 | 336 | 0.010 |
Why?
| Vascular Endothelial Growth Factor A | 1 | 2004 | 498 | 0.010 |
Why?
| Dose-Response Relationship, Drug | 1 | 2004 | 1842 | 0.010 |
Why?
| Moloney murine leukemia virus | 1 | 1996 | 11 | 0.010 |
Why?
| Zidovudine | 1 | 1996 | 77 | 0.010 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 1996 | 104 | 0.010 |
Why?
| Cats | 1 | 1996 | 193 | 0.010 |
Why?
| Virion | 1 | 1996 | 73 | 0.010 |
Why?
|
|
Gold's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|